A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer

Inclusion Criteria:

• Female patients with histopathologically proven metastatic breast cancer.
• Patients 18-75 years old
• Performance status: Karnofsky > 70%
• Patients must have measurable disease. Patients with only blastic bone lesions are ineligible.
• Adequate bone marrow, liver, renal and cardiac functions defined as:
• Ability to understand the study and give informed consent.
• Patients may not have received more than one prior chemotherapy for metastatic breast cancer. 5-FU or Taxol given as part of an adjuvant regimen will not render the patient ineligible.

Exclusion Criteria:

• Patients with brain metastasis, adequately treated and stable and not requiring continued steroid medication will be eligible if no progression for > 3 months.
• Patients who have received any anti-cancer investigational agent in the month prior to inclusion.
• Patients previously treated with docetaxel(Taxotere)or capecitabine (Xeloda).
• Patients with lack of physical integrity of the upper gastrointestinal tract, inability to swallow tablets or those who have malabsorption syndrome.
• Patients with renal impairment (creatinine clearance below 30 ml/min calculated according to Cockcroft and Gault, see Appendix D), since capecitabine is contraindicated in patients with severe renal impairment.